Mesoblast stock set for board refresh as two directors depart
Alpha Vantage · ad-hoc-news.de · · AI-summarised by FinFlash
Mesoblast is undergoing a board refresh as two directors, William Burns and Philip Krause, are departing. The company plans to recruit new directors with US and global commercial biopharma experience to support its commercial expansion following the US launch of Ryoncil, aiming to transition into a revenue-generating commercial enterprise.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.